ReviewFrontiers in cellular and infection microbiology2025
New antifungal strategies and drug development against WHO critical priority fungal pathogens.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026Review
- In silico pathway-based subtractive proteomics for identifying novel drug targets in Candida albicans with structure-guided drug repurposing of aspartate-semialdehyde dehydrogenase inhibitors.Journal of molecular modeling · 2026Article
- Beyond Tuberculosis: Unlocking the Antifungal Potential of Novel Isoniazid Derivatives against Non-ACS omega · 2026Article
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- In Vitro Anti-Journal of fungi (Basel, Switzerland) · 2026Article
- Nitroxoline exerts potent anti-Antimicrobial agents and chemotherapy · 2026Article
- Two closely related β-1,2-xylosyltransferases differentially impact fungal glycan synthesis.bioRxiv : the preprint server for biology · 2026Article
- Phage Display-Derived Peptides Have Neutralizing Activities Against Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2026Article
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- Fungi between threat and promise: global perspectives on health and innovation.Frontiers in microbiology · 2026Review
- Structural barriers to antifungal drug development.Frontiers in cellular and infection microbiology · 2026Review
- Rational Design and Optimization of MCh-AMP1: A Stable α-Helical Antifungal Peptide with Enhanced Activity AgainstDrug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections pose a significant threat to human health, particularly in immunocompromised individuals, driving a sustained increase in the demand for effective antifungal agents. These agents can be classified into several categories based on their mechanisms of action and chemical structures, including inhibitors of sterol synthesis, cell wall synthesis, DNA synthesis, and cell membrane function. Each class exerts its antifungal effects through distinct molecular pathways that disrupt fungal cell growth and reproduction. However, the clinical utility of current antifungal therapies is hindered by challenges such as the emergence of drug resistance, limited antifungal spectra, and adverse side effects. Consequently, the development of safe and efficacious antifungal agents remains a pressing need. This review provides a comprehensive overview of the classification and molecular mechanisms of antifungal drugs, discusses the current challenges in antifungal therapy, and explores potential strategies for future drug development, aiming to inform and advance antifungal research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.